SM Challenge
Competing to Master the Management of Nonadvanced SM
Mastocytosis.
Akin C, Arock M, Carter MC, et al. Nat Rev Dis Primers. 2025;11(1):30.
Tyrosine kinase inhibitors in non-advanced systemic mastocytosis.
Akin C. Immunol Allergy Clin N Am. 2023;43:743–750.
Management of Bone Health in Adult Mastocytosis
Degboé Y, Nezzar C, Alary P, et al. Curr Osteoporos Rep. 2025;23(1):10.
Avapritinib versus placebo in indolent systemic mastocytosis.
Gotlib J, Castells M, Elberink HO, et al. NEJM. 2023;2(6):EVIDoa2200339.
Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM patient survey.
Mesa RA, Sullivan EM, Dubinski D, et al. Cancer. 2022;128(20):3691-3699.
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A. Am J Hematol. 2023;98:1097-1116.
Mast cells, mastocytosis, and related disorders.
Theoharides TC, Valent P, Akin C. N Engl J Med. 2015;373(2):163-172.
Systemic mastocytosis: current status and challenges in 2024.
Ustun C, Karadag FK, Linden MA, et al. Blood Adv. 2025; 9(9):2048-2062
Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice.
Valent P, Hartmann K, Schwaab J, et al. J Allergy Clin Immunol. 2022;10(8):1999-2012.e1996.
Systemic mastocytosis: multidisciplinary approach.
Zanotti R, Tanasi I, Crosera L, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068.
Patient Videos
Indolent Systemic Mastocytosis (ISM): The Patient Experience
Listen to Barbara, Laura, and Mary Jane share their stories about being diagnosed and living with indolent SM.
Clinical Guidelines and Resources
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA, Orazi A, Hasserjian R, et al. Blood. 2016;127(20):2391-2405.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.
Khoury JD, Solary E, Abla O, et al. Leukemia. 2022;36(7):1703-1719.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, Orazi A, Hasserjian RP, et al. Blood. 2022;140(11):1200-1228.
NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Total Rise in Peripheral Tryptase After Systemic Event (TRIPTASE) Calculator
American Initiative in Mast Cell Diseases (AIM)
AIM is dedicated to advance the research, education, and treatment of mastocytosis and related mast cell diseases.
The European Competence Network on Mastocytosis (ECNM)
The goal of the ECNM is to improve disease-recognition, diagnosis, and therapy in patients with mastocytosis in Europe.
Patient Resources
The Mast Cell Disease Society, Inc. (TMS)
TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.
Genetic and Rare Diseases Information Center
GARD helps patients find information, services, experts, financial aid, and support groups.
National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
NCCN Guidelines for Patients: Systemic Mastocytosis.
National Comprehensive Cancer Network.
28
2026
SM Challenge
Competing to Master the Management of NonAdvanced SM
| Time: | 6:00 AM-8:00 AM ET |
| Venue: | Philadelphia Marriott Downtown |
| Location: | Philadelphia, PA |
| Faculty: | Brian Chernak, MD; Matthew P. Giannetti, MD ; Anne L. Maitland, MD, PhD |
28
2026
SM Challenge
Competing to Master the Management of NonAdvanced SM
| Time: | 6:30 AM-8:00 AM ET |
| Venue: | Live Stream |
| Location: | Live Stream |
| Faculty: | Brian Chernak, MD; Matthew P. Giannetti, MD ; Anne L. Maitland, MD, PhD |
